FDA — authorised 11 October 2019
- Application: NDA212268
- Marketing authorisation holder: HISAMITSU
- Local brand name: SECUADO
- Indication: SYSTEM — TRANSDERMAL
- Status: approved
🇺🇸 Adjunctive asenapine in United States
FDA authorised Adjunctive asenapine on 11 October 2019
Marketing authorisation
Adjunctive asenapine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Psychiatry approved in United States
Frequently asked questions
Is Adjunctive asenapine approved in United States?
Yes. FDA authorised it on 11 October 2019.
Who is the marketing authorisation holder for Adjunctive asenapine in United States?
HISAMITSU holds the US marketing authorisation.